Details

Last Funding Type

Grant

Last Funding Money Raised

$1M

Industries

Analytics,Genetics,Health Care,Medical,Medical Device

Founded date

Jul 1, 2013

Number Of Employee

11 - 50

Operating Status

Active

Fusion Genomics develops highly sensitive and massively multiplex DNA/RNA sequencing based diagnostics for infectious diseases. We seek to change the paradigm in both treatment of the individual (optimum genomic information for effective personalized therapy) and public health (information for development of transmission dynamic models, outbreak predictions & optimal vaccines).

Fusion Genomics ONETest platform enables accurate and simultaneous detection and discrimination of hundreds of pathogens. The ONETest platform consists of our patent-pending DNA/RNA capture technology called Quantum Probes. These are paired with fully optimized reagents into a ONETest kit for library preparation which is then used to sequence the sample on NGS machines (Illumina/Life). Results from the sequencing are analyzed using Fusion’s proprietary Fusion Cloud database and analytics suite.

The ONETest platform captures actionable genomic data at par with meta-genomic sequencing at a fraction of the cost. The advantages of the platform over PCR are: 1) Limits of detection up to 1,000x better; 2) High sensitivity and specificity; 3) Detail pathogen data including virulence and resistance markers; and 4) high number of organisms and variants targeted. Our Cloud and proprietary database enable us to not only give all relevant clinical data but also to do detail strain level analysis and combine other data (such as such as geo-tags) for surveillance, epidemiology and transmission dynamics studies.

Fusion Genomics develops tests for both the surveillance/research and clinical markets. Our two present test – Influenza ONETest and Avian Influenza Environmental DNA ONETest – have gained traction in the surveillance market in Canada and the EU. The AI eDNA ONETest proves our claims on high limit-of-detection, sensitivity and specificity by being the only test to date that can detect and genotype avian influenza from wetland sediments in wild bird habitats. Our upcoming Hepatitis C tests is similarly designed to give much improved clinically actionable data in a single test and we have a pipeline of other tests such as HPV, MDR/XDR Tuberculosis, blood screening multiplex, sepsis, etc.